drugset / Trial / NCT02230878

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42847922 in Healthy Participants

NCT02230878

Phase 1 Completed 40 enrolled Janssen-Cilag International NV
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to investigate the safety, tolerability, pharmacokinetic (the study of the way a drug enters and leaves the blood and tissues over time), dose-proportionality, accumulation, urinary excretion, pharmacodynamics (the study of how drugs act on the body) and sedative effects of JNJ-42847922 in healthy male and female participants.

Timeline

Start
2014-05
Primary completion
2014-11
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Seltorexant Small molecule 5 mg
Subject Seltorexant Small molecule 10 mg
Subject Seltorexant Small molecule 20 mg
Subject Seltorexant Small molecule 40 mg

Indications

No indication recorded.